APA (7th ed.) Citation

Lin, Q., Song, W., Xie, W., Deng, Y., Gong, Y., Liu, Y., . . . Gu, D. Sequential treatment of anti-PD-L1 therapy prior to anti-VEGFR2 therapy contributes to more significant clinical benefits in non-small cell lung cancer. Elsevier.

Chicago Style (17th ed.) Citation

Lin, Qiao-xin, et al. Sequential Treatment of Anti-PD-L1 Therapy Prior to Anti-VEGFR2 Therapy Contributes to More Significant Clinical Benefits in Non-small Cell Lung Cancer. Elsevier.

MLA (9th ed.) Citation

Lin, Qiao-xin, et al. Sequential Treatment of Anti-PD-L1 Therapy Prior to Anti-VEGFR2 Therapy Contributes to More Significant Clinical Benefits in Non-small Cell Lung Cancer. Elsevier.